Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
Journal of Clinical Epidemiology
|
April 18, 2022
Representativeness of trial participants: linking the EORTC boost-no boost trial to the Netherlands cancer registry
Anouk Neven, Marissa C van Maaren, Kay Schreuder, et al.
Cancer Epidemiology
|
April 8, 2011
Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study
Sanna A Mulder, Ries Kranse, Ronald A Damhuis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 18, 2010
Prediction of prostate cancer in unscreened men: external validation of a risk calculator
Heidi A van Vugt, Monique J Roobol, Ries Kranse, et al.
European Urology
|
August 16, 2011
Towards an optimal interval for prostate cancer screening
Pim J van Leeuwen, Monique J Roobol, Ries Kranse, et al.
European Urology
|
December 3, 2014
Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam
Leonard P Bokhorst, Ries Kranse, Lionne D F Venderbos, et al.
International Journal of Cancer
|
October 23, 2004
Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study
Ries Kranse, Pieter C Dagnelie, Monique C van Kemenade, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2012
Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort
Heidi A van Vugt, Ries Kranse, Ewout W Steyerberg, et al.
European Urology
|
January 14, 2014
A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality
Marco Zappa, Donella Puliti, Jonas Hugosson, et al.
Journal of Medical Screening
|
February 8, 2013
Excess all-cause mortality in the evaluation of a screening trial to account for selective participation
Ries Kranse, Pim J van Leeuwen, Timo Hakulinen, et al.
International Journal of Cancer
|
January 5, 2002
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial
Harry J de Koning, Anssi Auvinen, Antonio Berenguer Sanchez, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
Journal of Clinical Epidemiology
|
April 18, 2022
Representativeness of trial participants: linking the EORTC boost-no boost trial to the Netherlands cancer registry
Anouk Neven, Marissa C van Maaren, Kay Schreuder, et al.
Cancer Epidemiology
|
April 8, 2011
Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study
Sanna A Mulder, Ries Kranse, Ronald A Damhuis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 18, 2010
Prediction of prostate cancer in unscreened men: external validation of a risk calculator
Heidi A van Vugt, Monique J Roobol, Ries Kranse, et al.
European Urology
|
August 16, 2011
Towards an optimal interval for prostate cancer screening
Pim J van Leeuwen, Monique J Roobol, Ries Kranse, et al.
European Urology
|
December 3, 2014
Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam
Leonard P Bokhorst, Ries Kranse, Lionne D F Venderbos, et al.
International Journal of Cancer
|
October 23, 2004
Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study
Ries Kranse, Pieter C Dagnelie, Monique C van Kemenade, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2012
Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort
Heidi A van Vugt, Ries Kranse, Ewout W Steyerberg, et al.
European Urology
|
January 14, 2014
A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality
Marco Zappa, Donella Puliti, Jonas Hugosson, et al.
Journal of Medical Screening
|
February 8, 2013
Excess all-cause mortality in the evaluation of a screening trial to account for selective participation
Ries Kranse, Pim J van Leeuwen, Timo Hakulinen, et al.
International Journal of Cancer
|
January 5, 2002
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial
Harry J de Koning, Anssi Auvinen, Antonio Berenguer Sanchez, et al.
Page
of 4